Enrichment of adeno-associated virus serotype 5 full capsids by anion exchange chromatography with dual salt elution gradients.
暂无分享,去创建一个
Z. Debebe | Eric J. Yearley | A. Tracy | R. A. Lavoie | Srivatsan Ramesh | Amod Joshi | Matthew A Teten | J.T. Zugates | Andrew T Cheeseman | Julia M Freeman | Summer Swango | Jeremy Fitzpatrick | B. Hollers | Tyler K Lindgren | Amber N Kozak | Vinay K Kondeti | Mary K Bright | Jacob A Irwin | Michael Guerrero
[1] Hannah A. Blair. Valoctocogene Roxaparvovec: First Approval , 2022, Drugs.
[2] M. Biel,et al. Comparison of Different Liquid Chromatography-Based Purification Strategies for Adeno-Associated Virus Vectors , 2021, Pharmaceutics.
[3] Santoshkumar L. Khatwani,et al. Anion-exchange HPLC assay for separation and quantification of empty and full capsids in multiple adeno-associated virus serotypes , 2021, Molecular therapy. Methods & clinical development.
[4] Maryam T. Hussain,et al. Characterization of Recombinant Adeno-Associated Viruses (rAAVs) for Gene Therapy Using Orthogonal Techniques , 2021, Pharmaceutics.
[5] J. Schrag,et al. Development of a scalable and robust AEX method for enriched rAAV preparations in genome-containing VCs of serotypes 5, 6, 8, and 9 , 2021, Molecular therapy. Methods & clinical development.
[6] G. Berguig,et al. Comprehensive characterization and quantification of adeno associated vectors by size exclusion chromatography and multi angle light scattering , 2021, Scientific Reports.
[7] Thomas W. Powers,et al. Adeno-associated virus capsid assembly is divergent and stochastic , 2020, Nature Communications.
[8] John Pieracci,et al. Separating Empty and Full Recombinant Adeno‐Associated Virus Particles Using Isocratic Anion Exchange Chromatography , 2020, Biotechnology journal.
[9] Benjamin Adams,et al. Moving from the bench towards a large scale, industrial platform process for adeno‐associated viral vector purification , 2020, Biotechnology and bioengineering.
[10] Zeng-dian Zhao,et al. Hofmeister Series: Insights of Ion Specificity from Amphiphilic Assembly and Interface Property , 2020, ACS omega.
[11] T. Linke,et al. Developing an Anion Exchange Chromatography Assay for Determining Empty and Full Capsid Contents in AAV6.2 , 2019, Molecular therapy. Methods & clinical development.
[12] Wei-Chiang Chen,et al. Analytical strategies for quantification of adeno-associated virus (AAV) empty capsids to support process development. , 2019, Human gene therapy methods.
[13] Seng H. Cheng,et al. Universal Method for the Purification of Recombinant AAV Vectors of Differing Serotypes , 2017, Molecular therapy. Methods & clinical development.
[14] J. Heyda,et al. Beyond the Hofmeister Series: Ion-Specific Effects on Proteins and Their Biological Functions. , 2017, The journal of physical chemistry. B.
[15] T. Flotte. Empty Adeno-Associated Virus Capsids: Contaminant or Natural Decoy? , 2017, Human Gene Therapy.
[16] M. Jarrold,et al. Resolving Adeno-Associated Viral Particle Diversity With Charge Detection Mass Spectrometry. , 2016, Analytical chemistry.
[17] G. Liu,et al. Interactions between Polyelectrolyte Brushes and Hofmeister Ions: Chaotropes versus Kosmotropes. , 2015, Langmuir : the ACS journal of surfaces and colloids.
[18] R. Xu,et al. Scalable Downstream Strategies for Purification of Recombinant Adeno-Associated Virus Vectors in Light of the Properties , 2015, Current pharmaceutical biotechnology.
[19] Lin Zhao,et al. Changes of Water Hydrogen Bond Network with Different Externalities , 2015, International journal of molecular sciences.
[20] Michael A. Metrick,et al. Hofmeister ion effects on the solvation and thermal stability of model proteins lysozyme and myoglobin , 2015 .
[21] J. F. Wright,et al. Product-Related Impurities in Clinical-Grade Recombinant AAV Vectors: Characterization and Risk Assessment , 2014, Biomedicines.
[22] G. Gao,et al. Empty virions in AAV8 vector preparations reduce transduction efficiency and may cause total viral particle dose-limiting side effects , 2014, Molecular therapy. Methods & clinical development.
[23] M. R. Delgado Alvira,et al. Analysis of particle content of recombinant adeno-associated virus serotype 8 vectors by ion-exchange chromatography. , 2012, Human gene therapy methods.
[24] J. F. Wright,et al. Separation of adeno-associated virus type 2 empty particles from genome containing vectors by anion-exchange column chromatography. , 2007, Journal of virological methods.
[25] P. Cremer,et al. Interactions between macromolecules and ions: The Hofmeister series. , 2006, Current opinion in chemical biology.
[26] H. Mizukami,et al. Removal of empty capsids from type 1 adeno-associated virus vector stocks by anion-exchange chromatography potentiates transgene expression. , 2006, Molecular therapy : the journal of the American Society of Gene Therapy.
[27] J. F. Wright,et al. Identification of factors that contribute to recombinant AAV2 particle aggregation and methods to prevent its occurrence during vector purification and formulation. , 2005, Molecular therapy : the journal of the American Society of Gene Therapy.
[28] J. F. Wright,et al. AAV empty capsids: for better or for worse? , 2014, Molecular therapy : the journal of the American Society of Gene Therapy.
[29] A. Kamen,et al. Primary recovery and chromatographic purification of adeno-associated virus type 2 produced by baculovirus/insect cell system. , 2007, Journal of virological methods.